Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus

American Journal of Clinical Pathology

Volumn 129, Issue 4, 2008, Pages 592-605

  Lin, Fan ^a   Shi, Jianhui ^a   Liu, Haiyan ^a   Zhang, Jun ^b   Zhang, Ping L ^a   Wang, Hanlin L ^c   Yang, Ximing J ^d   Schuerch, Conrad ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clear cell carcinoma of ovary and uterus; Metastatic renal cell carcinoma; pVHL; von Hippel Lindau gene product

Indexed keywords

GENE PRODUCT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RABBIT ANTISERUM; VON HIPPEL LINDAU PROTEIN; TUMOR MARKER; VHL PROTEIN, HUMAN;

ARTICLE; BILE DUCT; BLADDER CARCINOMA; BRAIN HEMANGIOMA; BREAST CARCINOMA; CLEAR CELL CARCINOMA; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIOID CARCINOMA; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY TUBULE; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MESOTHELIOMA; METASTASIS; OVARY CARCINOMA; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS ISLET CELL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY; UTERUS CARCINOMA; WESTERN BLOTTING; ADENOCARCINOMA; ENZYME IMMUNOASSAY; FEMALE; KIDNEY TUMOR; MALE; METABOLISM; OVARY TUMOR; PATHOLOGY; UTERUS CANCER;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 42949164051     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/Q0FLUXFJ4FTTW1XR     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Sudarshan S, Linehan WM. Genetic basis of cancer of the kidney. Semin Oncol. 2006;33:544-551.
3. Eble JN, Togashi K, Pisani P. Renal cell carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:12-43. World Health Organization Classification of Tumours.
4. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29:747-754.
5. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
6. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms: frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113:374-382.
7. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody "renal cell carcinoma marker." Am J Surg Pathol. 2001;25:1485-1492.
8. Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res. 1989;49:1802-1809.
9. Liao SY, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997;57:2827-2831.
10. Jiang Z, Fanger GR, Woda BA, et al. Expression of α-methylacyl-CoA racemase (P504S) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol. 2003;34:792-796.
11. Lin F, Brown RE, Shen T, et al. Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas. Appl Immunohistochem Mol Morphol. 2004;12:153-159.
12. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22:6810-6818.
13. Tretiakova M, Turkyilmaz M, Chekmareva M, et al. Immunophenotyping of renal cell neoplasms using a tissue microarray. Mod Pathol. 2002;15:184A. Abstract 767.
14. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69-76.
15. Chuang ST, Chu P, Sugimura J, et al. Overexpression of glutathione S-transferase alpha; in clear cell renal cell carcinoma. Am J Clin Pathol. 2005;123:421-429.
16. Lin F, Yang WN, Yang XJ, et al. Expression of S-100 protein in renal cell neoplasms. Hum Pathol. 2006;37:460-470.
17. Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol. 2007;42:371-381.
18. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673-682.
19. Kim WY, Kaelin WG Jr. Molecular pathways in renal cell carcinoma: rationale for targeted treatment. Semin Oncol. 2006;33:588-595.
20. Abdulrahman M, Maina EN, Morris MR, et al. Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene. 2006;26:1661-1672.
21. Iliopoulos O, Kibel A, Gray S, et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995;1:822-826.
22. Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998;95:11661-11666.
23. Corless CL, Kibel AS, Iliopoulos O, et al. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997;28:459-464.
24. Lee S, Chen DY, Humphrey JS, et al. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A. 1996;93:1770-1775.
25. Los M, Jansen GH, Kaelin WG, et al. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest. 1996;75:231-238.
26. Sakashita N, Takeya M, Kishida T, et al. Expression of von Hippel-Lindau protein in normal and pathological human tissues. Histochem J. 1999;31:133-144.
27. Schraml P, Hergovich A, Hatz F, et al. Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression. Am J Pathol. 2003;163:1013-1020.
28. Ye Y, Vasavada S, Kuzmin I, et al. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer. 1998;78:62-69.
29. Skacel M, Skilton B, Pettay JD, et al. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Applied Immunohistochem Mol Morphol. 2002;10:1-6.
30. Hebert C, Norris K, Parashar P, et al. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol Cancer. 2006;5:1-11.
31. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059-2067.
32. Seizinger BR, Smith DI, Filling-Katz MR, et al. Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of von Hippel Lindau disease. Proc Natl Acad Sci U S A. 1991;88:2864-2868.
33. Kuzmin I, Duh FM, Latif F, et al. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene. 1995;10:2185-2194.
34. Nagashima Y, Miyagi Y, Udagawa K, et al. Von Hippel-Lindau tumour suppressor gene: localization of expression by in situ hybridization. J Pathol. 1996;180:271-274.
35. Lin F, Hull ME, Shi J, et al. Expression of S100A4, S100A6, and S100P in pancreatic and ampullary adenocarcinomas [abstract]. Mod Pathol. 2007;20:286A. Abstract 1313.
36. Simsir A, Palacios D, Linehan WM, et al. Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: utilization of microdissection and polymerase chain reaction in archival tissues. Diagn Cytopathol. 2001;24:328-332.
37. Dent J, Hall GD, Wilkinson N, et al. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridization. Br J Cancer. 2003;88:1578-1583.